Bioxodes is developing its lead program based on the Ir-CPI molecule. Ir-CPI is the first in a novel class of antithrombotics and potentially the world’s first injectable molecule which could be used in all patients groups with limited risk of bleeding and without the need to be reversed or washed out at the end of critical procedures.